Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve As per attachment.

pdf

Norris Medicines Ltd.

29 Apr 2025

16.85

4.98%

Corp. Note

Norris Medicines Ltd - 524414 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyNorris Medicines Ltd 2CIN NO.L24230GJ1990PLC086581 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 18.59 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYANKA LOHIYA Designation: Compliance Officer EmailId: cspriyankalohiya@gmail.com Name of the Chief Financial Officer: Iqubal Patel Designation: Chief Financial Officer EmailId: norrismedicines@gmail.com Date: 29/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf